Research Article| Volume 113, ISSUE 1, SUPPLEMENT 1, 45-54, July 08, 2002

Download started.


The expanding role of fluoroquinolones

  • Anthony J Schaeffer
    Requests for reprints should be addressed to Anthony J. Schaeffer, MD, Northwestern University Medical School, Department of Urology, Tarry 11-715, 303 East Chicago Avenue, T-229, Chicago, IL 60611-3008 USA
    Department of Urology, Northwestern University School of Medicine, Chicago, Illinois, USA
    Search for articles by this author


      There has been a growing rate of resistance among common urinary tract pathogens, such as Escherichia coli, to traditional antimicrobial therapies including the “gold standard” trimethoprim-sulfamethoxazole (TMP-SMX). Consequently, fluoroquinolone antimicrobial agents have taken on an expanding management role for UTIs. In fact, the recent Infectious Diseases Society of America clinical management guidelines for UTI recommend fluoroquinolones as first-line therapy for uncomplicated UTI in areas where resistance is likely to be of concern.
      Fluoroquinolones have demonstrated high bacteriologic and clinical cure rates, as well as low rates of resistance, among most common uropathogens. There are currently 7 fluoroquinolones with indications for UTI in the United States. However, only 3 are commonly used: levofloxacin, ciprofloxacin, and, to a lesser extent, gatifloxacin. Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence. In addition, levofloxacin and gatifloxacin have same-dose bioequivalency between their intravenous and oral formulations, allowing for “switch” or step-down therapy from parenteral to oral formulations of the same agent at the same dose.
      Fluoroquinolones are indicated for the management of acute uncomplicated UTIs, as well as complicated and severe UTI and pyelonephritis, in adults. They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance >10% to 20% to TMP-SMX, or who have risk factors for such resistance. Fluoroquinolone properties include a broad spectrum of coverage, low rates of resistance, and good safety profiles.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gupta K
        • Sahm D.F
        • Mayfield D
        • Stamm W.E
        Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women.
        Clin Infect Dis. 2001; 33: 89-94
      1. TSN Database, MRL Pharmaceutical Services.

        • Warren J.W
        • Abrutyn E
        • Hebel J.R
        • et al.
        Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women.
        Clin Infect Dis. 1999; 29: 745-758
        • Bertino J
        • Fish D
        The safety profile of fluoroquinolones.
        Clin Ther. 2000; 22: 798-817
        • Naber K.G
        • Hollauer K
        • Kirchbauer D
        • Witte W
        In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
        Int J Antimicrob Agents. 2000; 16: 239-243
        • Chan-Tack K.M
        Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999.
        South Med J. 2001; 94: 619-620
        • Akasaka T
        • Tanaka M
        • Yamaguchi A
        • Sato K
        Type II Topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999.
        Antimicrob Agents Chemother. 2001; 45: 2263-2268
        • Bonfiglio G
        Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?.
        Chemotherapy. 2001; 47: 239-242
        • Drago L
        • De Vecchi E
        • Mombelli B
        • et al.
        Activity of levofloxacin and ciprofloxacin against urinary pathogens.
        J Antimicrob Chemother. 2001; 48: 37-45
      2. Ciprofloxacin package insert. Bayer Corporation, West Haven, CT1997
      3. Enoxacin package insert. Aventis Pharmaceuticals, Parsippany, NJ2001
      4. Gatifloxacin package insert. Bristol-Myers Squibb Company, Princeton, NJ2001
      5. Levofloxacin package insert. Ortho-McNeil Pharmaceutical Inc, Raritan, NJ2001
      6. Lomefloxacin package insert. Unimed Pharmaceuticals, Deerfield, IL2001
      7. Norfloxacin package insert. Merck & Company, West Point, PA2001
      8. Ofloxacin package insert. Ortho-McNeil Pharmaceutical Inc, Raritan, NJ2001
      9. Trovafloxacin package insert. Roerig, Division of Pfizer, New York, NY1998
        • Jafri H.S
        • McCracken Jr, G.H
        Fluoroquinolones in paediatrics.
        Drugs. 1999; 58: 43-48
        • Segev S
        • Yaniv I
        • Haverstock D
        • Reinhart H
        Safety of long-term ciprofloxacin.
        Clin Infect Dis. 1999; 28: 299-308
        • Pryka R
        • Kowasksy S
        • Haverstock D
        Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia.
        Clin Ther. 1998; 20: 141-155
        • Schacht P
        • Arcieri G
        • Hullman R
        Safety of oral ciprofloxacin. An update based on clinical trial results.
        Am J Med. 1989; 87: 98S-102S
        • Deamer R.L
        • Prichard J.G
        • Luman G.J
        Hypersensitivity and anaphylactoid reactions to ciprofloxacin.
        Ann Pharmacother. 1992; 26: 1081-1084
        • Davis R
        • Markham A
        • Balfour J.A
        Drugs. 1996; 51: 1019-1074
        • Elston R.A
        • Taylor J
        Possible interaction of ciprofloxacin and cyclosporin A.
        J Antimicrob Chemother. 1988; 21: 674-680
        • Avent C.K
        • Krinsky D
        • Kirklin J.K
        • et al.
        Synergistic nephrotoxicity due to ciprofloxacin and cyclosporin A.
        Am J Med. 1988; 85: 452-453
        • McCarty J.M
        • Richard G
        • Huck W
        • et al.
        A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women.
        Am J Med. 1999; 106: 292-299
        • Raz R
        • Naber K.G
        • Raizenberg C
        • et al.
        Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women.
        Eur J Clin Microbiol Infect Dis. 2000; 19: 327-331
        • Talan D.A
        • Stamm W.E
        • Hooton T.M
        • et al.
        Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women.
        JAMA. 2000; 283: 1583-1590
        • Fish D.N
        • North D.S
        Gatifloxacin, an advanced 8-methoxy fluoroquinolone.
        Pharmacotherapy. 2001; 21: 35-59
        • Perry C.M
        • Barman Balfour J.A
        • Lamb H.M
        Drugs. 1999; 58: 683-696
        • Takahashi S
        • Ebisu H
        • Hirose T
        • et al.
        Bactericidal activity of gatifloxacin (AM-1155) against Pseudomonas aeruginosa and Enterococcus faecalis in an in vitro bladder model simulating human urinary concentrations after oral administration.
        Chemotherapy. 2000; 46: 122-128
        • Norrby S.R
        Expert Opin Pharmacother. 1999; 1: 109-119
        • Martin S.J
        • Jung R
        • Garvin C.G
        A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
        Drug Saf. 2001; 24: 199-222
        • File T.M
        • Segreti J
        • Dunbar L
        • et al.
        A multi-center randomized study comparing the efficacy and safety of IV and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia.
        Antimicrob Agents Chemother. 1997; 41: 1965-1972
        • Richard G.A
        • Klimberg I.N
        • Fowler C
        • Callery-D’Amico S
        A combined analysis of two studies comparing levofloxacin with two other fluoroquinolones for the treatment of acute pyelonephritis.
        (Abstract LM3)in: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 15–18, 1996 (New Orleans, LA.)
        • Habib M.P
        • Gentry L.O
        • Rodriguez-Gomez G
        • et al.
        Multi-center, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbation of chronic bronchitis.
        Infect Dis Clin Pract. 1998; 7: 101-109
        • Nicodemo A.C
        • Robledo J.A
        • Jasovich A
        • Neto W
        A multicenter, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
        Int J Clin Pract. 1998; 52: 69-74
        • North D.S
        • Fish D.N
        • Redington J.J
        Levofloxacin, a second-generation fluoroquinolone.
        Pharmacotherapy. 1998; 18: 915-935
        • Davis R
        • Bryson H.M
        Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
        Drugs. 1994; 47: 677-700
        • Wagai N
        • Yoshida M
        • Takayama S
        Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice.
        Arzneimittelforschung. 1992; 42: 404-405
        • Lipsky B.A
        • Baker C.A
        Fluoroquinolone toxicity profiles.
        Clin Infect Dis. 1999; 28: 352-364
        • Richard G.A
        • Childs S
        • Fowler C
        • et al.
        A comparison of levofloxacin and ciprofloxacin for the treatment of complicated urinary tract infections.
        Clin Infect Dis. 1996; 23 (Abstract 293.): 913
        • Richard G.A
        • Klimberg I.N
        • Fowler C.L
        • et al.
        Levofloxacin versus ciprofloxacin versus lemofloxacin in acute pyelonephritis.
        Urology. 1998; 51: 51-55
        • Klimberg I.W
        • Cox II, C.E
        • Fowler C.L
        • et al.
        A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.
        Urology. 1998; 51: 610-615
        • Patel S.S
        • Spencer C.M
        Drugs. 1996; 51: 137-160
        • Naber K.G
        • Well M
        • Hollauer K
        • Kirchbauer D
        • Witte W
        In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
        Chemotherapy. 1998; 44: 77-84
        • Beringer P.M
        • Wong-Beringer A
        • Rho J.P
        Economic aspects of antibacterial adverse effects.
        Pharmacoeconomics. 1998; 13: 35-49
        • Gottlieb P.L
        Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection.
        Clin Ther. 1995; 17: 493-502
        • Brumfitt W
        • Hamilton-Miller J.M
        • Walker S
        Enoxacin relieves symptoms of recurrent urinary infections more rapidly than cefuroxime axetil.
        Antimicrob Agents Chemother. 1993; 37: 1558-1559
        • Donabedian H
        • O’Donnell E
        • Drill C
        • Lipton L.M
        • Khuder S.A
        • Burnham J.C
        Prevention of subsequent urinary tract infections in women by the use of anti-adherence antimicrobial agents.
        J Antimicrob Chemother. 1995; 35: 409-420
        • Guibert J
        • Herman H
        • Capron M.H
        Treatment of uncomplicated recurrent cystitis in women.
        Contracept Fertil Sex. 1997; 25: 79-84
        • Ball P
        • Tillotson G
        Tolerability of fluoroquinolone antibiotics. Past, present and future.
        Drug Saf. 1995; 13: 343-358
        • Goettsch W
        • van Pelt W
        • Nagelkerke N
        • et al.
        Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands.
        J Antimicrob Chemother. 2000; 46: 223-228
        • Schaeffer A.J
        • Stuppy B.A
        Efficacy and safety of self-start therapy in women with recurrent urinary tract infections.
        J Urol. 1999; 161: 207-211
        • Well M
        • Naber K.G
        • Kinzig-Schippers M
        • Sorgel F
        Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
        Int J Antimicrob Agents. 1998; 10: 31-38
        • Sandberg T
        • Englund G
        • Lincoln K
        • Nilsson L.G
        Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.
        Eur J Clin Microbiol Infect Dis. 1990; 9: 317-323
        • Miano L
        • Goldoni S
        • Tubaro A
        • et al.
        Review of norfloxacin in lower urinary tract infections.
        Eur Urol. 1990; 17: 13-18
        • Seidmon E.J
        • Krisch E.B
        • Truant A.L
        • et al.
        Treatment of recurrent urinary tract infections with norfloxacin versus trimethoprim-sulfamethoxazole.
        Urology. 1990; 35: 187-193
        • Jonsson M
        • Englund G
        • Norgard K
        Norfloxacin vs pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients.
        Scand J Infect Dis. 1990; 22: 339-344
        • Mavromanolakis E
        • Maraki S
        • Samonis G
        • Tselentis Y
        • Cranidis A
        Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections.
        J Chemother. 1997; 9: 203-207
        • Ortiz J
        • Vila M.C
        • Soriano G
        • et al.
        Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
        Hepatology. 1999; 29: 1064-1069
        • Kania I
        • Gospodarek E
        • Ulatowska B
        Analysis of the bacterial strains isolated from urine samples of hospitalized and ambulatory patients.
        Med Sci Monit. 2000; 6: 1122-1127
        • Hooton T.M
        • Johnson C
        • Winter C
        • et al.
        Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women.
        Antimicrob Agents Chemother. 1991; 35: 1479-1483
        • Reid G
        • Potter P
        • Delaney G
        • et al.
        Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury.
        Int J Antimicrob Agents. 2000; 13: 305-307
        • Henry D
        • Ellison W
        • Sullivan J
        • et al.
        Treatments of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi-Center UUTI Study Group.
        Antimicrob Agents Chemother. 1998; 42: 2262-2266
        • Christ W
        Central nervous system toxicity of quinolones.
        J Antimicrob Chemother. 1990; 26: 219-225
        • Naber K.G
        Survey on antibiotic usage in the treatment of urinary tract infections.
        J Antimicrob Chemother. 2000; 46 (63–65): 49-52
        • Ravnan S.L
        • Locke C
        Levofloxacin and warfarin interaction.
        Pharmacotherapy. 2001; 21: 884-885
        • Marchbanks C.R
        Drug-drug interactions with fluoroquinolones.
        Pharmacotherapy. 1993; 13: 23S-28S